Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Splice donor and acceptor sequences are short, highly conserved nucleotide motifs at the exon-intron boundaries in eukaryotic genes. The splice donor site is located at the 5' end of the intron and almost always features the dinucleotide "GU" (and less commonly GC or AT), while the splice acceptor site is at the 3' end and is usually "AG". The correct identification and processing of these sites by the spliceosome ensures removal of introns and ligation of exons to create mature mRNA. Mutations in these consensus sequences (splice site mutations) can cause mis-splicing, leading to retention of introns or skipping of exons, often resulting in nonfunctional or deleterious proteins, and are a significant cause of genetic diseases. These sites are not themselves drug targets, but rather regulatory genomic elements critical for normal gene expression and are a focus for genetic diagnosis and gene therapy development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Splice donor sequence and splice acceptor sequence.